146 related articles for article (PubMed ID: 3124738)
1. Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.
Bayer AS; Selecky M; Babel K; Hirano L; Yih J; Parr TR
Antimicrob Agents Chemother; 1987 Nov; 31(11):1750-5. PubMed ID: 3124738
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo bacterocodal interactions of clindamycin and ceftazidime, by non-beta-lactamase mechanisms, in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive beta-lactamase overproducing strain.
Bayer AS; Lindsay P; Parr TR
J Antimicrob Chemother; 1988 Oct; 22(4):529-39. PubMed ID: 3144525
[TBL] [Abstract][Full Text] [Related]
3. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Hirano L; Yih J
Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985
[TBL] [Abstract][Full Text] [Related]
4. Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Peters J; Parr TR; Chan L; Hancock RE
Antimicrob Agents Chemother; 1987 Feb; 31(2):253-8. PubMed ID: 3105450
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.
Bayer AS; Lindsay P; Yih J; Hirano L; Lee D; Blomquist IK
Antimicrob Agents Chemother; 1986 Oct; 30(4):528-31. PubMed ID: 3539007
[TBL] [Abstract][Full Text] [Related]
6. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
8. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.
Fantin B; Pangon B; Potel G; Caron F; Vallée E; Vallois JM; Mohler J; Buré A; Philippon A; Carbon C
Antimicrob Agents Chemother; 1990 Apr; 34(4):581-6. PubMed ID: 2188586
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Bayer AS; Norman D; Kim KS
Antimicrob Agents Chemother; 1985 Dec; 28(6):781-5. PubMed ID: 3909954
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
Pefanis A; Giamarellou H; Karayiannakos P; Donta I
Antimicrob Agents Chemother; 1993 Feb; 37(2):308-13. PubMed ID: 8452362
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection.
Ciofu O; Bagge N; Høiby N
APMIS; 2002 Dec; 110(12):881-91. PubMed ID: 12645667
[TBL] [Abstract][Full Text] [Related]
12. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
19. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
20. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
